ABOUT
THIS PROSPECTUS SUPPLEMENT
This
prospectus supplement and the accompanying base prospectus is part of a registration statement that we filed with the Securities
and Exchange Commission (“SEC”) utilizing a “shelf” registration process. Each time we conduct an offering
to sell securities under the accompanying base prospectus we will provide a prospectus supplement that will contain specific information
about the terms of that offering, including the price, the amount of securities being offered and the plan of distribution. The
shelf registration statement was initially filed with the SEC on April 18, 2014, and was declared effective by the SEC on May
12, 2014. This prospectus supplement describes the specific details regarding this offering and may add, update or change information
contained in the accompanying base prospectus. The accompanying base prospectus provides general information about us, some of
which, such as the section entitled “Plan of Distribution,” may not apply to this offering. This prospectus supplement
and the accompanying base prospectus are an offer to sell only the securities offered hereby, but only under circumstances and
in jurisdictions where it is lawful to do so.
If
information in this prospectus supplement is inconsistent with the accompanying base prospectus or the information incorporated
by reference, you should rely on this prospectus supplement. This prospectus supplement, together with the base prospectus and
the documents incorporated by reference into this prospectus supplement and the base prospectus, includes all material information
relating to this offering. We have not authorized anyone to provide you with different or additional information and you must
not rely on any unauthorized information or representations. You should assume that the information appearing in this prospectus
supplement, the accompanying base prospectus, and the documents incorporated by reference in this prospectus supplement and the
accompanying base prospectus is accurate only as of the respective dates of those documents. Our business, financial condition,
results of operations and prospects may have changed since those dates.
You should carefully read this prospectus supplement,
the base prospectus, the information and documents incorporated herein by reference and the additional information under the heading
“Where You Can Find More Information” before making an investment decision
.
We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference into this prospectus supplement or the accompanying base prospectus were made solely
for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties
to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants
should not be relied on as accurately representing the current state of our affairs.
Unless
otherwise mentioned or unless the context requires otherwise, all references in this prospectus to “our Company,”
“we,” “us,” “our” and “OncoSec” refer to OncoSec Medical Incorporated, a Nevada
corporation. We own the registered trademarks or trademark applications for OncoSec™, ImmunoPulse™ and NeoPulse™.
All other trademarks, trade names and service marks included or incorporated by reference into this prospectus supplement, the
accompanying base prospectus and any applicable free writing prospectus are the property of their respective owners.
|
|
|
|
PROSPECTUS
SUMMARY
|
|
|
|
|
|
This
prospectus summary highlights information contained elsewhere in this prospectus supplement, the accompanying base prospectus
and the documents incorporated by reference. This summary does not contain all of the information that you should consider
before deciding to invest in our securities. You should read this entire prospectus supplement and the accompanying base prospectus
carefully, including the section entitled “Risk Factors” beginning on page S-4 and our consolidated financial
statements and the related notes and the other information incorporated by reference into this prospectus supplement and the
accompanying base prospectus, before making an investment decision.
|
|
|
|
|
|
Our
Company
|
|
|
|
|
|
As
a biotechnology company, our mission is to focus on the advancement of immune system-stimulating treatments, with a focus
on discovering and developing novel immuno-oncology therapies. Our portfolio includes biologic immunology therapeutic product
candidates intended to treat a wide range of tumor types. Our technology also includes intellectual property relating to our
ImmunoPulse™ delivery technology. ImmunoPulse™ is an electroporation delivery device that we use in combination
with our therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, to deliver
the therapeutic directly into the tumor and promote an inflammatory response against the cancer. This unique therapeutic modality
is intended to reverse the immunosuppressive microenvironment in the tumor and engender a systemic anti-tumor response against
untreated tumors in other parts of the body. Our electroporation devices consist of an electrical pulse generator and disposable
applicators, which can be adapted to treat different tumor types.
|
|
|
|
|
|
In
August 2015, we enrolled the first patient into the Phase II investigator sponsored clinical trial led by the University of
California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of ImmunoPulse™
IL-12, and Merck’s approved anti-PD-1 agent, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic
melanoma. The primary endpoint is the best Overall Response Rate (bORR) of the combination regimen in patients whose tumors
are characterized by low numbers of tumor-infiltrating lymphocytes. We currently are on track to complete enrollment by the
end of calendar year 2016.
|
|
|
|
|
|
In
September 2015, we announced the results from a Phase II clinical trial of ImmunoPulse™ IL-12 in patients with Merkel
cell carcinoma (“MCC”). In the MCC study led by the University of Washington, 79% of patients (11/14) showed an
increase in IL-12 protein levels in tumor biopsy samples obtained approximately 22 days after treatment compared to baseline,
indicating that ImmunoPulse™ IL-12 leads to successful DNA transfection and sustained protein expression within the
tumor microenvironment. ImmunoPulse™ IL-12 was well-tolerated, with no treatment-related adverse events above Grade
2 and no treatment-related serious adverse events. The most common adverse event was Grade 1 transient pain associated with
the treatment procedure. This was a proof-of-concept study and with our announcement of these results, we do not plan to further
advance the MCC program.
|
|
|
|
|
|
Toward
the end of October 2015, we enrolled the first patient in our biomarker-focused pilot study of ImmunoPulse™ IL-12 in
patients with triple negative breast cancer (“TNBC”). We anticipate enrolling approximately 10 patients in the
TNBC pilot study, led by Stanford University, with the primary objective of the study to evaluate the potential of ImmunoPulse™
IL-12 to promote a pro-inflammatory molecular and histological signature in tumor samples and the secondary objectives include
the evaluation of safety and tolerability; evaluation of local ablation effect (% of necrosis) and description of other evidence
of anti-tumor activity. We currently are on track to complete enrollment by the end of calendar year 2016.
|
|
|
|
|
|
In
the second quarter of fiscal year 2016, we decided to pause further enrollment in our head and neck clinical trial to focus
our development efforts toward a potential registration pathway for metastatic melanoma and to pursue clinically relevant
data in breast cancer and additional combination trials.
|
|
|
|
|
|
Corporate
Information
|
|
|
|
|
|
We
were incorporated under the laws of the State of Nevada on February 8, 2008 under the name Netventory Solutions Inc. to pursue
the business of inventory management solutions. Effective March 1, 2011, we completed a merger with our subsidiary, OncoSec
Medical Incorporated, a Nevada corporation, for the sole purpose of changing our name to “OncoSec Medical Incorporated.”
Our principal executive offices are located at 5820 Nancy Ridge Drive, San Diego, California 92121. The telephone number at
our principal executive office is (855) 662-6732. Our website address is www.oncosec.com. Information contained on our website
is not deemed part of this prospectus supplement.
|
|
|
|
|
|
Risk
Factors
|
|
|
|
|
|
Our
business is subject to substantial risks. Please carefully consider the “Risk Factors” beginning on page S-4 of
this prospectus supplement and the other information included and incorporated by reference in this prospectus supplement
for a discussion of the factors you should consider carefully before deciding to purchase the securities offered by this prospectus
supplement. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair
our business operations. You should be able to bear a complete loss of your investment.
|
|
|
|
|
|
|
|
|
The
Offering
The
following is a brief summary of some of the terms of the offering and is qualified in its entirety by reference to the
more detailed information appearing elsewhere in this prospectus supplement and the accompanying prospectus. For a more
complete description of the terms of our common stock and the warrants, see the “Description of Securities”
and the “Description of Capital Stock” section in the accompanying base prospectus.
|
|
|
|
|
|
Securities
Offered in This Offering
|
|
665,049
shares of our common stock, par value $0.0001 per share, pre-funded Series B warrants to purchase 4,844,593 shares of our
common stock and Series A warrants to purchase up to 5,509,642 shares of our common stock .
|
|
|
|
|
|
|
|
Description
of Series A Warrants
|
|
The
shares of common stock or Series B warrants, as applicable, and Series A warrants will
be sold together as one share of common stock or a Series B warrant to purchase one share
of common stock, as applicable, and one Series A warrant to purchase one share of common
stock. The shares of common stock or Series B warrants, as applicable, and the Series
A warrants are immediately separable upon issuance. Each Series A warrant will have an
exercise price of $1.69 per share, will be exercisable upon issuance and will expire
nine years from the date of issuance.
|
|
|
|
|
|
|
|
Description
of Pre-funded Series B Warrants
|
|
The
pre-funded Series B warrants are being issued to prevent the beneficial ownership of a purchaser in this offering (together
with its affiliates and certain related parties) of our common stock from exceeding 4.99%. Each Series B warrant will have
an exercise price of $0.01 per shares, will be exercisable upon issuance and will expire only when exercised in full. As stated
above, purchasers of Series B warrants will also receive Series A warrants as if such purchasers were buying shares of our
common stock in this offering.
|
|
|
|
|
|
|
|
Offering
Price
|
|
$1.815
per share of common stock and accompanying Series A warrant to purchase one share of
our common stock.
$1.805
per Series B warrant to purchase one share of our common stock and accompanying Series A warrant to purchase one share
of our common stock.
|
|
|
|
|
|
|
|
Common
Stock Outstanding Before This Offering
|
|
16,971,214
shares. (1)
|
|
|
|
|
|
|
|
Common
Stock to be Outstanding After This Offering
|
|
17,636,263
shares, excluding shares issuable upon exercise of the Series A warrants, Series B warrants and warrants being issued to the
placement agent. (1)
|
|
|
|
|
|
|
|
Use
of Proceeds
|
|
We
expect to use the net proceeds received from this offering for general corporate purposes, including clinical trial expenses
and research and development expenses. See “Use of Proceeds” on page S-10.
|
|
|
|
|
|
|
|
Risk
Factors
|
|
See
“Risk Factors” beginning on page S-4 and the other information included in this prospectus supplement or
incorporated herein by reference for a discussion of factors you should carefully consider before deciding to invest in our
common stock.
|
|
|
|
|
|
|
|
Symbol
|
|
Our
shares of common stock are quoted for trading on the NASDAQ Capital Market under the symbol “ONCS.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Excludes the following:
|
|
|
|
|
|
|
|
|
●
|
3,461,399
shares of common stock issuable upon exercise of options outstanding as of May 20, 2016, of which approximately 1,628,245
shares are exercisable as of May 20, 2016;
|
|
|
|
|
|
|
|
|
●
|
680,000
shares of common stock issuable upon the vesting and settlement of restricted stock units outstanding as of May 20, 2016;
|
|
|
|
|
|
|
|
|
●
|
157,469
shares of common stock reserved for issuance and available for future grant under our 2011 Stock Incentive Plan (as amended)
as of May 20, 2016;
|
|
|
|
|
|
|
|
|
●
|
3,000,875
shares of common stock issuable upon exercise of warrants outstanding as of May 20, 2016, which have exercise prices ranging
from $4.375 to $24.00 per share;
|
|
|
|
|
|
|
|
|
●
|
500,000
shares of common stock reserved for issuance and available for future grant under our Employee Stock Purchase Plan;
|
|
|
|
|
|
|
|
|
●
|
5,509,642
shares of common stock issuable upon exercise of the Series A warrants being offered in this offering, which have an exercise
price of $1.69 per share;
|
|
|
|
|
|
|
|
|
●
|
4,844,593
shares of common stock issuable upon exercise of the Series B warrants being offered in this offering, which have an exercise
price of $0.01 per share; and
|
|
|
|
|
|
|
|
|
●
|
275,482
shares of common stock issuable upon exercise of warrants issuable to the placement agent in connection with this offering,
which have an exercise price of $2.26875 per share.
|
|
|
|
|
|
|
RISK
FACTORS
Investing
in our common stock involves a high degree of risk. You should carefully consider the risk factors described below and the risk
factors incorporated by reference to our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and all other
information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, including
our financial statements and the related notes, as updated by our subsequent filings under the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), and in any free writing prospectus that we have authorized for use in connection
with this offering before acquiring any of our common stock. These risks could have a material and adverse impact on our business,
results of operations, financial condition and growth prospects, which may cause the trading price of our common stock to decline,
or on the trading price of our common stock itself. As a result, you could lose all or part of your investment.
Risks
Related to this Offering and Our Common Stock
Our
management will have broad discretion over the use of the net proceeds from this offering.
We
currently anticipate using the net proceeds from this for general corporate purposes, including clinical trial expenses and research
and development expenses. We have not reserved or allocated specific amounts for these purposes and we cannot specify with certainty
how we will use the net proceeds. Accordingly, our management will have considerable discretion in the application of the net
proceeds and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being
used appropriately. The net proceeds may be used for corporate purposes that do not increase our operating results or market value.
Until the net proceeds are used, they may be placed in investments that do not produce income or that lose value.
Our
common stock has low trading volume and the price of our common stock has been, and will likely continue to be, highly volatile.
Trading
of our common stock is frequently highly volatile, with low trading volume. We have experienced, and are likely to continue experiencing,
significant fluctuations in the stock price and trading volume. There is no assurance that a sufficient market will develop in
our stock, in which case it could be difficult for stockholders to sell their stock. Furthermore, the volatility of our stock
price could negatively impact our ability to raise capital or acquire businesses or technologies. In addition to the risks and
uncertainties described in this prospectus supplement and in the documents incorporated by reference herein, other factors affecting
the trading price and trading volume of our common stock may include:
|
●
|
adverse
research and development or clinical trial results;
|
|
|
|
|
●
|
conducting
open-ended clinical trials which could lead to results (success or setbacks) being obtained by the public prior to a formal
announcement by us;
|
|
|
|
|
●
|
our
inability to obtain additional capital;
|
|
|
|
|
●
|
announcement
that the U.S. Food and Drug Administration has denied our request to approve our products for commercialization in the United
States, or similar denial by other regulatory bodies which make independent decisions outside the United States;
|
|
|
|
|
●
|
potential
negative market reaction to the terms or volume of any issuance of shares of our capital stock to new investors or service
providers;
|
|
|
|
|
●
|
sales
of substantial amounts of our common stock, or the perception that substantial amounts of our common stock will be sold, by
us or our stockholders in the public market;
|
|
|
|
|
●
|
declining
working capital to fund operations, or other signs of apparent financial uncertainty;
|
|
|
|
|
●
|
significant
advances made by competitors that adversely affect our potential market position; and
|
|
|
|
|
●
|
the
loss of key personnel and the inability to attract and retain additional highly-skilled personnel.
|
We
will need to raise additional capital in future periods to continue operating our business, and such additional funds may not
be available on acceptable terms or at all.
We
do not generate any cash from operations and will need to raise additional funds in future periods in order to continue operating
our business. We have a history of raising funds through offerings of our common stock, and we may in the future raise additional
funds through public or private equity offerings, debt financings, or corporate collaborations and licensing arrangements. We
expect to continue to fund our operations primarily through equity and debt financings in the near future. If additional capital
is not available, we may not be able to continue to operate our business or we may have to significantly change our business plan
or discontinue our operations entirely.
We
will require additional financing to fund our planned operations, including developing and commercializing our intellectual property,
seeking to license or acquire new assets, researching and developing any potential patents, related compounds and other intellectual
property, funding potential acquisitions, and supporting clinical trials and seeking regulatory approval relating to our assets
and any assets we may acquire in the future. Additional financing may not be available to us when needed or, if available, may
not be available on commercially reasonable terms. If we issue equity or convertible debt securities to raise additional funds,
our existing stockholders, including investors in this offering, may experience substantial dilution, and the new equity or debt
securities may have rights, preferences and privileges senior to those of our existing stockholders, including investors in this
offering. If we incur debt, it may increase our leverage relative to our earnings or to our equity capitalization, requiring us
to pay additional interest expenses. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities
and future cash commitments.
We
may not be able to obtain additional financing if the volatile and uncertain conditions in the capital and financial markets,
and more particularly the market for early-development-stage biotechnology and life science company stocks, persist. Weak economic
and capital markets conditions could result in increased difficulties in raising capital for our operations. We may not be able
to raise money through the sale of our equity securities or through borrowing funds on terms we find acceptable. If we cannot
raise the funds that we need, we will be unable to continue our operations, and our stockholders, including investors in this
offering, could lose their entire investment in our Company.
We
have never paid dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future.
The
continued operation and potential expansion of our business will require substantial funding. Investors seeking cash dividends
in the foreseeable future should not purchase our common stock. We have paid no cash dividends on any of our capital stock to
date and we do not anticipate paying any cash dividends on our common stock in the foreseeable future, as we intend to retain
our available cash to fund the development and growth of our business. Any determination to pay dividends in the future will be
at the discretion of our Board of Directors and will depend upon our results of operations and financial condition, contractual
restrictions, restrictions imposed by applicable law, and other factors our Board of Directors deems relevant. Any return to stockholders
will therefore be limited to the appreciation of their stock, which may never occur.
If
we issue additional shares in the future, our existing stockholders, including investors who purchase shares in this offering,
will be diluted.
Our
articles of incorporation authorize the issuance of up to 160,000,000 shares of common stock with a par value of $0.0001 per share.
In addition to capital raising activities, other possible business and financial uses for our authorized common stock include,
without limitation, future stock splits, acquiring other companies, businesses, or products in exchange for shares of common stock,
issuing shares of our common stock to partners in connection with strategic alliances, attracting and retaining employees by the
issuance of additional securities under our various equity compensation plans, or other transactions and corporate purposes that
our Board of Directors deems are in the Company’s best interest. Additionally, shares of common stock could be used for
anti-takeover purposes or to delay or prevent changes in control or management of the Company. We cannot provide assurances that
any issuances of common stock will be consummated on favorable terms or at all, that they will enhance stockholder value, or that
they will not adversely affect our business or the trading price of our common stock. The issuance of any such shares will reduce
the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock,
including shares issued in this offering. If we issue any such additional shares, such issuance will reduce the proportionate
ownership and voting power of all current stockholders, including investors who purchase shares in this offering. Further, such
issuance may result in a change of control of our company.
Sales
of common stock by our stockholders, or the perception that such sales may occur, could depress our stock price.
The
market price of our common stock could decline as a result of sales by, or the perceived possibility of sales by, our existing
stockholders, including investors in this offering. Since March 2011, we have completed a number of offerings of our common stock
and warrants. Future sales of common stock by significant stockholders, including by those who acquired their shares in our prior
offerings or who are affiliates, or the perception that such sales may occur, could depress the price of our common stock.
If
outstanding options and warrants to purchase shares of our common stock are exercised, outstanding restricted stock units vest
and settle, or additional shares are issued under our Employee Stock Purchase Plan, the interests of our stockholders could be
diluted.
As
of May 20, 2016, we have outstanding (i) options to purchase 3,461,399 shares of common stock, (ii) warrants to purchase 3,000,875
shares of our common stock and (ii) restricted stock units for which 680,000 shares of our common stock are issuable upon the
vesting and settlement. In addition, as of May 20, 2016, we have 157,469 shares reserved for future issuance under our 2011 Stock
Incentive Plan (as amended) and 500,000 shares reserved for future issuance under our Employee Stock Purchase Plan. The exercise
of options and warrants, the vesting and settlement of restricted stock units, the issuance of additional shares of common stock
or other equity awards under our 2011 Stock Incentive Plan (as amended) or our Employee Stock Purchase Plan, and the sale of any
resulting shares of our common stock in connection with the foregoing, could have an adverse effect on the market for our common
stock, including the price that an investor could obtain for their shares. Investors may experience dilution in the net tangible
book value of their investment upon the exercise of outstanding options and warrants or vesting and settlement of outstanding
restricted stock units granted under our stock option plans, and options, warrants and restricted stock units that may be granted
or issued in the future. In future periods, we may elect to reduce the exercise price of outstanding warrants as a means of providing
additional financing to us.
We
may not be able to realize value from, or otherwise preserve and utilize, our net operating loss (NOL) carryforwards.
Significant
equity restructuring often results in an Internal Revenue Section 382 ownership change that limits the future use of net operating
loss (NOL) carryforwards and other tax attributes. In the event that we undergo such an ownership change, our NOL carryforwards
generated prior to the ownership change would be subject to annual limitations, which could reduce, eliminate, or defer the utilization
of these losses. Further, the recognition and measurement of our NOL carryforwards may include estimates and judgments by our
management, and the Internal Revenue Service has not audited or otherwise validated the amount of our NOL carryforwards. Additionally,
legislative changes could negatively impact our ability to use any tax benefits associated with our NOL carryforwards. If we put
in place limitations on ownership of our common stock or adopt a shareholder rights plan to preserve our ability to use NOL carryforwards,
this could deter potential buyers of our common stock and adversely impact the trading price of our common stock.
If
our common stock is delisted from The Nasdaq Capital Market or we are found noncompliant with Nasdaq regulations, our stock’s
market price and liquidity could be negatively impacted.
Our
listing on The Nasdaq Capital Market is contingent upon our meeting all the continued listing requirements. If we are found noncompliant
by The Nasdaq Capital Market, or if our common stock is delisted from The Nasdaq Capital Market, our stock price could be negatively
impacted, our stock’s liquidity could be reduced, and our ability to raise capital in the future may be limited.
The
Series A warrants and Series B warrants are new issues of securities with no established trading market.
The
Series A warrants and Series B warrants are each a new issue of securities with no established trading market. The Series A warrants
and Series B warrants will not be listed on any securities exchange and we do not expect them to be quoted on any quotation system.
A trading market for the Series A warrants and Series B warrants is not expected to develop, and even if a market develops it
may not provide meaningful liquidity. The absence of a trading market or liquidity for the Series A warrants and Series B warrants
may adversely affect their value.
If
all Series B Warrants were immediately exercised, you would experience immediate dilution in the net-tangible book value per share
of the common stock you purchase or the common stock you receive upon exercise of the Series B warrants
The
assumed public offering price per share of our common stock in this offering is substantially higher than the book value per share
of our common stock. However, the offering also includes pre-funded Series B warrants with an aggregate purchase price together
with the accompanying series A warrants of $8.7 million, which effectively will increase the net-tangible book value per share
of common stock. As a result, while investors purchasing shares of common stock in this offering will experience an immediateincrease
of $0.325 per share in the net tangible book value of the common stock purchased, based on an assumed public offering price of
$1.815 per share, if all of the series B warrants are exercised in full today, investors in the offering would suffer immediate
and substantial dilution per share in the net-tangible book value of the common stock purchased or received upon exercise of the
Series B warrants.
FORWARD-LOOKING
STATEMENTS
This
prospectus supplement, the accompanying base prospectus and the documents we have filed with the SEC that are incorporated herein
by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the
“Securities Act”) and Section 21E of the Exchange Act. In addition, from time to time we or our representatives have
made or will make forward-looking statements in various other filings that we make with the SEC or in other documents, including
press releases or other similar announcements. Forward-looking statements concern our current plans, intentions, beliefs, expectations
and statements of future economic performance. Statements containing terms such as “will,” “may,” “believe,”
“do not believe,” “plan,” “expect,” “intend,” “estimate,” “anticipate”
and other phrases of similar meaning are considered to be forward-looking statements.
Forward-looking
statements are based on our assumptions and are subject to known and unknown risks and uncertainties that could cause actual results
to differ materially from those reflected in or implied by these forward-looking statements. Factors that might cause actual results
to differ include, without limitation, those set forth under “Risk Factors” in this prospectus supplement and those
discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operation,” in our
most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and in our future periodic reports filed with the SEC.
Readers are cautioned not to place undue reliance on any forward-looking statements contained in this prospectus supplement, the
accompanying base prospectus or the documents we have filed with the SEC that are incorporated herein by reference, which reflect
management’s views and opinions only as of their respective dates. We assume no obligation to update forward-looking statements
to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements, except
to the extent required by applicable securities laws. You are advised, however, to consult any additional disclosures we have
made or will make in the filings we make with the SEC, including reports on Forms 10-K, 10-Q and 8-K. All subsequent forward-looking
statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements
contained in this prospectus supplement, the accompanying base prospectus or any related issuer free writing prospectus.
USE
OF PROCEEDS
We
estimate the net proceeds to us from the sale of the securities offered hereby, after deducting estimated placement agent fees
and our other estimated offering expenses, will be approximately $9.1 million. If a warrant holder elects to exercise the warrants
issued in this offering, we may also receive proceeds from the exercise of the warrants. We cannot predict when or if the warrants
will be exercised. It is possible that the warrants may expire and may never be exercised.
We
expect to use the net proceeds from this offering (including any resulting from the exercise of warrants, if any) for general
corporate purposes, including clinical trial expenses and research and development expenses. We may also use a portion of these
proceeds for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that
complement our business, although we have no current understandings, commitments, or agreements to do so. If we receive the maximum
amount of proceeds to be potentially obtained in this offering, we expect such proceeds would provide funding for our operations
through the first quarter of the Company’s 2018 fiscal year.
The
amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under “Risk
factors” in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein,
as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other
purposes, and our management will have significant flexibility in applying the net proceeds of this offering. Until the funds
are used as described above, we intend to invest the net proceeds from this offering in interest-bearing money market accounts
and short-term certificates of deposit.
DESCRIPTION
OF SECURITIES
We
are offering up to 665,049 shares of our common stock, Series A warrants to purchase up to 5,509,642 shares of our common stock
and Series B warrants to purchase up to 4,844,593 shares of our common stock. This prospectus supplement also relates to the offering
of shares of our common stock upon the exercise, if any, of the Series A warrants and Series B warrants issued in this offering.
Common
Stock
Pursuant
to our articles of incorporation, we are currently authorized to issue 160,000,000 shares of common stock, par value $0.0001 per
share. As of May 20, 2016, there were 16,971,214 shares of our common stock outstanding.
Voting
Rights
The
outstanding shares of our common stock are fully paid and non-assessable. Holders of our common stock are entitled to one vote,
in person or by proxy, for each share held of record on all matters submitted to a vote of the stockholders. Except as otherwise
provided by applicable law, holders of our common stock are not entitled to cumulative voting of their shares in elections of
directors.
Dividends
Subject
to the provisions of applicable law, including the Nevada Revised Statutes, the holders of shares of our common stock are entitled
to receive, when and as declared by the board of directors, dividends or other distributions (whether payable in cash, property,
or securities of OncoSec) out of the assets of OncoSec legally available for such dividends or other distributions.
Other
Rights
No
stockholder of OncoSec has any preemptive right under our articles of incorporation to subscribe for, purchase, or otherwise acquire
shares of any class or series of capital stock of OncoSec. The shares of our common stock are not subject to redemption by operation
of a sinking fund or otherwise. In the event of any liquidation, dissolution, or winding up of OncoSec, subject to the rights,
if any, of the holders of other classes of our capital stock, the holders of shares of our common stock are entitled to receive
any of our assets available for distribution to our stockholders ratably in proportion to the number of shares held by them.
Our
common stock is traded on the NASDAQ Capital Market under the symbol “ONCS”.
Warrants
The
material terms and provisions of the warrants being offered pursuant to this prospectus supplement and the accompanying prospectus
are summarized below. This summary is subject to and qualified in its entirety by the form of Series A warrant and form of pre-funded
Series B warrant, which will be provided to each investor in this offering and are filed on a Current Report on Form 8-K in connection
with this offering.
Series
A Warrants
We
are offering Series A warrants to purchase up to 5,509,642 shares of our common stock to purchasers in this offering. Each Series
A warrant has an exercise price of $1.69 per share. The Series A warrants are exercisable upon issuance and have an exercise term
equal to nine years. The exercise of the Series A warrants is subject to certain exercise limitations, such that the holder may
not exercise the Series A warrants if such exercise results in the holder (together with its affiliates and certain related parties)
becoming the beneficial owner of more than 4.99% of the number of shares of common stock outstanding immediately after giving
effect to such exercise, provided that upon at least 61 days prior notice to us, the holder may increase or decrease such limitation
up to a maximum of 9.99% of the number of shares of common stock outstanding. Each Series A warrant will have a cashless exercise
right in the event that the shares of common stock underlying such warrants are not covered by an effective registration statement
at the time of such exercise.
The
Series A warrants provide for the adjustment of the exercise price and number of shares issuable upon exercise of the warrants
in connection with stock dividends and splits, such that the number of shares issuable upon exercise of the Series A warrant is
adjusted in proportion to the change in the number of shares outstanding and the aggregate exercise price of the Series A warrant
remains unchanged. In addition, if we grant, issue or sell any common stock equivalents or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of shares of common stock (and not the holder of the
Series A warrant), then the Series A warrant holder will be entitled to acquire, upon the terms applicable to such purchase rights,
the aggregate purchase rights which the holder could have acquired if the holder had held the number of shares of common stock
acquirable upon complete exercise of the Series A warrant. If we declare or make any dividend or other distribution of our assets
to holders of our common stock, the Series A warrant holder shall be entitled to participate in the distribution to the same extent
that the holder would have participated therein if the holder had held the number of shares of common stock acquirable upon complete
exercise of the Series A warrant. Other than as described above, the Series A warrants do not contain anti-dilution provisions.
Upon
the reclassification, reorganization or recapitalization of our common stock, our merger or consolidation with or into another
entity, the consummation of a stock purchase agreement whereby more than 50% of the outstanding shares of the common stock are
acquired by another person or entity, or a sale or other disposition of substantially all of our assets, the holder of each of
the Series A warrants is entitled to receive the number of shares of our common stock or the common stock of our successor or
acquirer that such holder would have been entitled to receive immediately prior to such transaction, and the exercise price for
such shares shall be adjusted based on the amount of any alternate consideration receivable as a result of such transaction by
a holder of the number of shares of common stock for which the Series A warrant is exercisable immediately prior to such transaction.
The holder of the Series A warrant may also require us or any successor entity to purchase the Series A warrant from the holder
by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the Series
A warrant on the date of the consummation of the transaction.
The
Series A warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice. No fractional shares of common stock will be issued in connection with the exercise of a Series A warrant. Subject to
applicable laws, the Series A warrants may be offered for sale, sold, transferred or assigned without our consent. We do not plan
on applying to list the Series A warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally
recognized trading system. Except as otherwise provided in the Series A warrants or by virtue of such holder’s ownership
of shares of our common stock, the holder of a Series A warrant does not have the rights or privileges of a holder of our common
stock, including any voting rights, until the holder exercises the Series A warrant. Amendments and waivers of the terms of the
Series A warrants require the written consent of the holder of such Series A warrant and us.
Pre-funded
Series B Warrants
We
are offering pre-funded Series B warrants to purchase up to 4,844,593 shares of our common stock. Each Series B warrant has an
exercise price of $0.01 per share. The Series B warrants are exercisable at any time after their original issuance until exercised
in full. The exercise of the Series B warrants is subject to certain exercise limitations, such that the holder may not exercise
the Series B warrants if such exercise results in the holder becoming the beneficial owner of more than 4.99% of the number of
shares of common stock outstanding immediately after giving effect to such exercise, provided that upon at least 61 days prior
notice to us, the holder may increase or decrease such limitation up to a maximum of 9.99% of the number of shares of common stock
outstanding. Each Series B warrant will have a cashless exercise right in the event that the shares of common stock underlying
such warrants are not covered by an effective registration statement at the time of such exercise.
The
Series B warrants provide for the adjustment of the exercise price and number of shares issuable upon exercise of the Series B
warrants in connection with stock dividends and splits, such that the number of shares issuable upon exercise of the Series B
warrant is adjusted in proportion to the change in the number of shares outstanding and the aggregate exercise price of the Series
B warrant remains unchanged. In addition, if we grant, issue or sell any common stock equivalents or rights to purchase stock,
warrants, securities or other property pro rata to the record holders of any class of shares of common stock (and not the holder
of the Series B warrant), then the Series B warrant holder will be entitled to acquire, upon the terms applicable to such purchase
rights, the aggregate purchase rights which the holder could have acquired if the holder had held the number of shares of common
stock acquirable upon complete exercise of the Series B warrant. If we declare or make any dividend or other distribution of our
assets to holders of our common stock, the Series B warrant holder shall be entitled to participate in the distribution to the
same extent that the holder would have participated therein if the holder had held the number of shares of common stock acquirable
upon complete exercise of the Series B warrant. Other than as described above, the Series B warrants do not contain anti-dilution
provisions.
Upon
the reclassification, reorganization or recapitalization of our common stock, our merger or consolidation with or into another
entity, the consummation of a stock purchase agreement whereby more than 50% of the outstanding shares of the common stock are
acquired by another person or entity, or a sale or other disposition of substantially all of our assets, the holder of each of
the Series B warrants is entitled to receive the number of shares of our common stock or the common stock of our successor or
acquirer that such holder would have been entitled to receive immediately prior to such transaction, and the exercise price for
such shares shall be adjusted based on the amount of any alternate consideration receivable as a result of such transaction by
a holder of the number of shares of common stock for which the Series B warrant is exercisable immediately prior to such transaction.
The holder of the Series B warrant may also require us or any successor entity to purchase the Series B warrant from the holder
by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the Series
B warrant on the date of the consummation of the transaction.
The
Series B warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice. No fractional shares of common stock will be issued in connection with the exercise of a Series B warrant. Subject to
applicable laws, the Series B warrants may be offered for sale, sold, transferred or assigned without our consent. We do not plan
on applying to list the Series B warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally
recognized trading system. Except as otherwise provided in the Series B warrants or by virtue of such holder’s ownership
of shares of our common stock, the holder of a Series B warrant does not have the rights or privileges of a holder of our common
stock, including any voting rights, until the holder exercises the Series B warrant. Amendments and waivers of the terms of the
Series B warrants require the written consent of the holder of such Series B warrant and us.
PLAN
OF DISTRIBUTION
We
are offering 665,049 shares of our common stock, Series A warrants to purchase 5,509,642 shares of our common stock and pre-funded
Series B warrants to purchase up to 4,844,593 shares of our common stock. This prospectus supplement also relates to the offering
of shares of our common stock upon the exercise, if any, of the Series A warrants and Series B warrants issued in this offering.
We
have entered into a securities purchase agreement directly with the investors in this offering. The securities purchase agreement
contains customary representations, warranties and covenants for transactions of this type. These representations, warranties
and covenants were made solely for purposes of the securities purchase agreement and should not be relied upon by any of our investors
who are not parties to the agreement, nor should any such investor rely upon any descriptions thereof as characterizations of
the actual state of facts or conditions. Such investors are not third-party beneficiaries under the securities purchase agreement.
We
are offering the securities to the investors through H.C. Wainwright & Co., LLC (“Wainwright”), which has agreed
to act as our exclusive placement agent in connection with the offering pursuant to the terms of a placement agent agreement with
us. The placement agent is not purchasing the securities offered by us and is not required to arrange the purchase or sale of
any specific number or dollar amount of securities, but rather has agreed, subject to the terms and conditions of the placement
agent agreement, to use its reasonable best efforts to arrange for the sale of the securities by introducing us to selected institutional
investors who will purchase the securities offered in this offering directly from us. The placement agent agreement terminates
upon the closing of this offering or may be terminated by the placement agent or us at any time upon ten days prior written notice.
We
have agreed to pay the placement agent a placement fee equal to 5% of the aggregate gross proceeds to us from the sale of securities
in this offering (excluding any proceeds from
the exercise of the Series A warrants and Series B warrants). We have engaged Maxim and Raymond James as financial advisors with
respect to the offering, and have agreed to pay $150,000 to each of Maxim and Raymond James, respectively, in consideration for
their financial advisory services. We estimate total expenses of this offering, excluding the placement agent fees and reimbursements
and financial advisory fees, will be approximately $90,000.
The following table shows the per share and total fees we will
pay to the placement agent, assuming the sale of all of the securities offered hereby.
Per share of common stock and Series A warrant to purchase one share of common stock
|
|
$
|
0.09075
|
|
Per Series B warrant to purchase one share of our common stock and Series
A warrant to purchase one share of common stock
|
|
$
|
0.09025
|
|
Total
|
|
$
|
497,577.72
|
|
In
addition to the cash fees set forth above, we have agreed to issue to Wainwright warrants to purchase up to an aggregate of
5% of the aggregate number of shares of common stock sold in the offering, including all of the shares issuable upon exercise
of the Series B warrants, assuming such warrants were immediately exercised in full, and excluding any shares of common stock
issuable upon exercise of the Series A warrants. The placement agent warrant shall have substantially the same terms as the
Series A warrants offered in this offering, except that the expiration date will be May 24, 2021, the exercise price is
$2.26875, the placement agent warrants do not have anti-dilution protections and the placement agent warrants are not
transferable for 180 days from the date of the closing of the offering, except the transfer of any security:
|
●
|
by
operation of law or by reason of reorganization of our company;
|
|
|
|
|
●
|
to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction set forth above for the remainder of the time period;
|
|
●
|
if
the aggregate amount of securities of our company held by the holder of the compensation warrants or related persons do not
exceed 1% of the securities being offered;
|
|
|
|
|
●
|
that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10%
of the equity in the fund; or
|
|
|
|
|
●
|
the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction set forth above
for the remainder of the time period.
|
Neither
the warrants nor the shares underlying the warrants to be issued to our placement agent and our financial advisors for this offering
are being registered under the registration statement of which this prospectus supplement forms a part. The placement agent shall
also be entitled to the foregoing cash and warrant compensation with respect to any investors introduced by the placement agent
to us that invest in any subsequent capital-raising transaction during the 6 month period following the termination of the placement
agent agreement.
We
have agreed to indemnify the placement agent against certain liabilities under the Securities Act. The placement agent may be
deemed to be an underwriter within the meaning of Section 2(a)(ii) of the Securities Act and any commissions received by it and
any profit realized on the sale of securities by it while acting as principal might be deemed to be underwriting discounts or
commissions under the Securities Act. The placement agent is required to comply with the requirements of the Securities Act and
the Exchange Act, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
may limit the timing of purchases and sales of shares of common stock and warrants to purchase shares of common stock by the placement
agent. Under these rules and regulations, the placement agent many not (i) engage in any stabilization activity in connection
with our securities or (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities,
other than as permitted under the Exchange Act, until it has completed its participation in the distribution. The placement agent
has informed us that it will not engage in overallotment, stabilizing transactions or syndicate covering transactions in connection
with this offering.
We
currently anticipate that the closing of the sale of the shares of common stock offered pursuant to this prospectus supplement
will take place on or about May 26, 2016. The placement agent agreement provides that the obligations of the placement agent and
the investors to close this offering are subject to certain conditions, including the absence of any material adverse change in
our business and the receipt of customary legal opinions, letters and certificates.
This
prospectus supplement will be distributed to the investors who agree to purchase the securities and will inform the investors
of the closing date as to such securities. The investors will also be informed of the date and manner in which they must transmit
the purchase price for their shares. We will deposit the shares of our common stock with The Depository Trust Company once the
funds to purchase such shares have been received. At the closing, The Depository Trust Company will credit the shares to the account
of the investors.
The
foregoing descriptions of the securities purchase agreement and the placement agent agreement are only summaries, do not purport
to be complete and are qualified in their entirety by reference to the securities purchase agreement and the placement agent agreement,
copies of which are attached as exhibits to our Current Report on Form 8-K filed with the SEC in connection with this offering
and are incorporated herein by reference.
Our
common stock is quoted for trading on the NASDAQ Capital Market under the symbol “ONCS.” The transfer agent for our
common stock is Nevada Agency and Transfer Company. Our transfer agent’s address is 50 West Liberty Street, Suite 880, Reno,
Nevada 89501.
LEGAL
MATTERS
The
validity of the securities offered by this prospectus supplement will be passed upon for us by McDonald Carano Wilson LLP, Reno,
Nevada and certain other legal matters will be passed upon for us by Morrison & Foerster LLP, San Diego, California. Ellenoff
Grossman & Schole, LLP, New York, New York, is acting as counsel for the placement agent in connection with this offering.
EXPERTS
The
financial statements and the Company’s assessment of the effectiveness of internal control over financial reporting incorporated
in this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended July 31, 2015 have been so incorporated
in reliance on the report of Mayer Hoffman McCann P.C., an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The
SEC allows us to “incorporate by reference” the information we file with it. This means that we can disclose important
information to you in this prospectus by referring you to another document. The information incorporated by reference is considered
to be a part of this prospectus supplement. We incorporate by reference the documents listed below that we have previously filed
with the SEC (excluding any portions of any Form 8-K that are not deemed “filed” pursuant to the General Instructions
of Form 8-K):
|
●
|
our
Annual Report on Form 10-K for the fiscal year ended July 31, 2015 filed with the SEC on October 14, 2015 (including portions
of our definitive Proxy Statement for our Fiscal Year 2015 Annual Meeting incorporated therein by reference);
|
|
|
|
|
●
|
our
Quarterly Reports on Form 10-Q for the quarters ended October 31, 2015 and January 31, 2016 filed with the SEC on December
8, 2015 and March 8, 2016, respectively;
|
|
|
|
|
●
|
our
Current Reports on Form 8-K filed with the SEC on August 5, 2015, October 30, 2015, October 30, 2015, November 5, 2015, December
7, 2015, December 29, 2015, January 26, 2016 and April 15, 2016; and
|
|
|
|
|
●
|
the
description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on May 27, 2015, including
any amendments or reports filed for the purpose of updating such description.
|
We
also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, but excluding any information deemed furnished
and not filed with the SEC. Any statement contained in a previously filed document is deemed to be modified or superseded for
purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or in a subsequently
filed document incorporated by reference herein modifies or supersedes the statement.
We
will provide without charge to each person, including any beneficial owner, to whom a prospectus supplement is delivered, on written
or oral request of that person, a copy of any or all of the documents we are incorporating by reference into this prospectus supplement,
other than exhibits to those documents unless such exhibits are specifically incorporated by reference into those documents. Such
written requests should be addressed to:
OncoSec
Medical Incorporated
5820
Nancy Ridge Drive
San
Diego, California 92121
Attention:
Investor Relations
You
may also make such requests by contacting us at (858) 662-6732.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement under the Securities Act that registers the securities offered hereby. The registration
statement, including the exhibits and schedules attached thereto and the information incorporated by reference therein, contains
additional relevant information about the securities and our Company, which we are allowed to omit from this prospectus supplement
pursuant to the rules and regulations of the SEC. In addition, we file annual, quarterly and current reports and proxy statements
and other information with the SEC. You may read and copy any document that we file at the SEC’s Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference
Room. Our SEC filings are also available on the SEC’s website at http://www.sec.gov. Copies of certain information filed
by us with the SEC are also available on our website at http://www.oncosec.com. We have not incorporated by reference into this
prospectus supplement the information on our website, and you should not consider it to be a part of this document.
PROSPECTUS
$75,000,000
ONCOSEC
MEDICAL INCORPORATED
By
this prospectus, we may offer, from time to time:
|
●
Common
stock
|
|
●
Warrants
|
|
●
Debt securities
|
All
of the securities listed above may be sold separately or as units with other securities.
This
prospectus may not be used to sell securities unless accompanied by a prospectus supplement, which will describe the method and
the terms of the offering. We will provide you with specific amount, price and terms of the applicable offered securities in one
or more supplements to this prospectus. You should read this prospectus and any supplement carefully before you purchase any of
our securities.
Our
common stock is listed on OTC Markets Group, Inc.’s OTCQB tier (“OTCQB”) under the symbol “ONCS.”
On May 6, 2014, the closing price of our common stock on the OTCQB was $0.77 per share.
Investing
in our securities involves risk. Please carefully read the information under “Risk Factors” beginning on page 3 for
information you should consider before investing in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
We
may offer the securities in amounts, at prices and on terms determined at the time of offering. We may sell the securities directly
to you, through agents we select, or through underwriters and dealers we select. If we use agents, underwriters or dealers to
sell the securities, we will name them and describe their compensation in a prospectus supplement. In addition, the underwriters
may overallot a portion of the securities. For additional information regarding the methods of sale of our securities, you should
refer to the section entitled “Plan of Distribution” in this prospectus.
This
prospectus is dated May 12, 2014
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or
the SEC, using a “shelf” registration process. Under this shelf process, we may, from time to time, offer or sell
any combination of the securities described in this prospectus in one or more offerings.
This
prospectus provides you with a general description of the securities offered by us. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may
also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent, information
in this prospectus is superseded by the information in the prospectus supplement.
The
prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities
offered; the initial public offering price; the price paid for the securities; net proceeds; and the other specific terms related
to the offering of the securities.
You
should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or
issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make
any representations in connection with this offering other than those contained or incorporated by reference in this prospectus,
any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described
herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized
by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an
offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person
to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration
statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement,
including its exhibits. You should read the entire prospectus and any prospectus supplement and any related issuer free writing
prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related
issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus
supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information
contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as
of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable.
PROSPECTUS
SUMMARY
The
following summary highlights information contained in this prospectus or incorporated by reference. While we have included what
we believe to be the most important information about our company and this offering, the following summary may not contain all
the information that may be important to you. You should read this entire prospectus carefully, including the risks of investing
discussed under “Risk Factors” beginning on page 3, the information to which we refer you and the information
incorporated into this prospectus by reference, for a complete understanding of our business and this offering. References in
this prospectus to “our company,” “we,” “our,” “OncoSec” and “us”
refer to OncoSec Medical Incorporated, a Nevada corporation.
OncoSec
Medical Incorporated
Overview
We
are an emerging drug-medical device and therapeutic company focused on designing, developing and commercializing innovative and
proprietary medical approaches for the treatment of solid tumors where currently approved therapies are inadequate based on their
efficacy or side-effects. Initially, we provided online inventory services to small and medium sized companies. In March 2011,
we acquired certain assets related to the use of drug-medical device combination products for the treatment of various cancers.
With this acquisition, we have abandoned our efforts in the online inventory services industry and are focusing our efforts in
the biomedical industry. Our goal is to improve the lives of people suffering from the life-altering effects of cancer through
the development of our novel treatment approaches.
Corporate
Information
We
were incorporated under the laws of the State of Nevada on February 8, 2008 under the name Netventory Solutions Inc. to pursue
the business of inventory management solutions. Effective March 1, 2011, we completed a merger with our subsidiary, OncoSec
Medical Incorporated, a Nevada corporation which was incorporated solely to effect a change in our name. As a result, we have
changed our name from “Netventory Solutions Inc.” to “OncoSec Medical Incorporated”. Our principal executive
offices are located at 5820 Nancy Ridge Drive, San Diego, California 92121. The telephone number at our principal executive office
is (858) 662-6732. Our website address is www.oncosec.com. Information contained on our website is not deemed part of this prospectus.
The
Securities We May Offer
We
may offer up to $75.0 million of common stock, warrants and debt securities in one or more offerings and in any combination. This
prospectus provides you with a general description of the securities we may offer. A prospectus supplement, which we will provide
each time we offer securities, will describe the specific amounts, prices and terms of these securities.
We
may sell the securities to or through underwriters, dealers or agents or directly to purchasers or as otherwise set forth below
under “Plan of Distribution.” We, as well as any agents acting on our behalf, reserve the sole right to accept and
to reject in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth the names of any
underwriters, dealers, agents or other entities involved in the sale of securities described in that prospectus supplement and
any applicable fee, commission or discount arrangements with them.
Common
Stock
We
may offer shares of our common stock, par value $0.0001 per share, either alone or underlying other registered securities convertible
into our common stock. Holders of our common stock are entitled to receive dividends declared by our board of directors out of
funds legally available for the payment of dividends. Currently, we do not pay a dividend. Each holder of common stock is entitled
to one vote per share. The holders of common stock have no preemptive rights.
Warrants
We
may issue warrants for the purchase of common stock or debt securities. We may issue warrants independently or together with other
securities.
Debt
Securities
We
may offer secured or unsecured obligations in the form of one or more series of senior or subordinated debt. The senior debt securities
and the subordinated debt securities are together referred to in this prospectus as the “debt securities.” The senior
debt securities will have the same rank as all of our other unsubordinated debt. The subordinated debt securities generally will
be entitled to payment only after payment of our senior debt. Senior debt generally includes all debt for money borrowed by us,
except debt that is stated in the instrument governing the terms of that debt to be not senior to, or to have the same rank in
right of payment as, or to be expressly junior to, the subordinated debt securities. We may issue debt securities that are convertible
into shares of our common stock.
The
senior and subordinated debt securities will be issued under separate indentures between us and a trustee. We have summarized
the general features of the debt securities to be governed by the indentures. These indentures have been filed as exhibits to
the registration statement of which this prospectus forms a part. We encourage you to read these indentures. Instructions on how
you can get copies of these documents are provided under the heading “Where You Can Find More Information.”
RISK
FACTORS
An
investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities
will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing
in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in
the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the
prospectus supplement or appearing or incorporated by reference in this prospectus. Each of the referenced risks and uncertainties
could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment
in our securities.
FORWARD-LOOKING
STATEMENTS
This
prospectus and the registration statement of which it forms a part, any prospectus supplement, any related issuer free writing
prospectus and the documents incorporated by reference into these documents contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements deal with our current plans, intentions, beliefs and expectations and statements of future economic performance. Statements
containing terms such as “believe,” “do not believe,” “plan,” “expect,” “intend,”
“estimate,” “anticipate” and other phrases of similar meaning are considered to contain uncertainty and
are forward-looking statements. In addition, from time to time we or our representatives have made or will make forward-looking
statements orally or in writing. Furthermore, such forward-looking statements may be included in various filings that we make
with the SEC, or press releases or oral statements made by or with the approval of one of our authorized executive officers. These
forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could
cause actual results to differ materially from those reflected in these forward-looking statements. Factors that might cause actual
results to differ include, but are not limited to, those set forth under Item 1A, “Risk Factors,” and Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operation,” in our most recent Annual Report on Form 10-K
and in our future filings made with the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements
contained in this prospectus, any prospectus supplement or any related issuer free writing prospectus, which reflect management’s
opinions only as of their respective dates. Except as required by law, we undertake no obligation to revise or publicly release
the results of any revisions to any forward-looking statements. You are advised, however, to consult any additional disclosures
we have made or will make in our reports to the SEC on Forms 10-K, 10-Q and 8-K. All subsequent written and oral forward-looking
statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements
contained in this prospectus, any prospectus supplement or any related issuer free writing prospectus.
RATIO
OF EARNINGS TO FIXED CHARGES
The
following table sets forth our ratio of earnings to fixed charges on a historical basis for each of the periods indicated. You
should read these ratios in connection with our consolidated financial statements, including the notes to those statements, incorporated
by reference in this prospectus.
|
|
Fiscal
Year Ended July 31,
|
|
(In thousands, except
ratios)
|
|
2009*
|
|
|
2010*
|
|
|
2011
|
|
|
2012
|
|
|
2013
|
|
Ratio of earnings to fixed charges
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Deficiency of earnings to fixed charges
|
|
|
34
|
|
|
|
37
|
|
|
|
3,800
|
|
|
|
2,400
|
|
|
|
7,150
|
|
*Prior
to March 2011, we provided online inventory solutions. In March 2011, we abandoned our efforts in the online inventory
services industry and are focusing our efforts in the biomedical industry. We are a development stage biomedical company; therefore,
our ratio coverage is less than 1:1.
USE
OF PROCEEDS
Unless
otherwise indicated in the prospectus supplement, the net proceeds from the sale of securities offered by this prospectus will
be used for general corporate purposes and working capital requirements, which may include, among other things, the repayment
or repurchase of debt obligations and other capital expenditures. We may also use a portion of the net proceeds for licensing
or acquiring intellectual property or technologies to incorporate into our products and product candidates or our research and
development programs, capital expenditures, to fund possible investments in and acquisitions of complementary businesses or partnerships.
We have not determined the amounts we plan to spend on the areas listed above or the timing of these expenditures, and we have
no current plans with respect to acquisitions as of the date of this prospectus. As a result, unless otherwise indicated in the
prospectus supplement, our management will have broad discretion to allocate the net proceeds of the offerings. Pending their
ultimate use, we intend to invest the net proceeds in a variety of securities, including commercial paper, government and non-government
debt securities and/or money market funds that invest in such securities.
DIVIDEND
POLICY
We
have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common
stock for the foreseeable future. We intend to use all available cash and liquid assets in the operation and growth of our business.
Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend
upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as our board of
directors deems relevant.
DESCRIPTION
OF CAPITAL STOCK
General
The
following summary of the material features of our capital stock does not purport to be complete and is subject to, and qualified
in its entirety by, the provisions of our articles of incorporation, as amended, our amended and restated bylaws, the Nevada Revised
Statutes and other applicable law. For information on how to obtain copies of our articles of incorporation and bylaws, which
are exhibits to the registration statement of which this prospectus is a part, see “Where You Can Find More Information.”
Pursuant
to our articles of incorporation, we are currently authorized to issue 3,200,000,000 shares of common stock, par value $0.0001
per share. As of April 17, 2014, there were 215,937,083 shares of our common stock outstanding.
Common
stock
Voting
Rights
The
outstanding shares of our common stock are fully paid and non-assessable. Holders of our common stock are entitled to one vote,
in person or by proxy, for each share held of record on all matters submitted to a vote of the stockholders. Except as otherwise
provided by applicable law, holders of our common stock are not entitled to cumulative voting of their shares in elections of
directors.
Dividends
Subject
to the provisions of applicable law, including the Nevada Revised Statutes, the holders of shares of our common stock are entitled
to receive, when and as declared by the board of directors, dividends or other distributions (whether payable in cash, property,
or securities of OncoSec) out of the assets of OncoSec legally available for such dividends or other distributions.
Other
Rights
No
stockholder of OncoSec has any preemptive right under our articles of incorporation to subscribe for, purchase, or otherwise acquire
shares of any class or series of capital stock of OncoSec. The shares of our common stock are not subject to redemption by operation
of a sinking fund or otherwise. In the event of any liquidation, dissolution, or winding up of OncoSec, subject to the rights,
if any, of the holders of other classes of our capital stock, the holders of shares of our common stock are entitled to receive
any of our assets available for distribution to our stockholders ratably in proportion to the number of shares held by them.
Our
common stock is traded on the OTCQB Marketplace under the symbol “ONCS”.
Liability
and Indemnification of Directors and Officers
The
Nevada Revised Statutes provide us with the power to indemnify any of our directors and officers. The director or officer must
have conducted himself/herself in good faith and reasonably believe that his/her conduct was in, or not opposed to, our best interests.
In a criminal action, the director or officer must not have had reasonable cause to believe his/her conduct was unlawful.
Under
applicable sections of the Nevada Revised Statutes, advances for expenses may be made by agreement if the director or officer
affirms in writing that he/she believes he/she has met the standards and will personally repay the expenses if it is determined
the officer or director did not meet the standards.
Our
bylaws include an indemnification provision under which we must indemnify any of our directors or officers, or any of our former
directors or officers, to the full extent permitted by law. If Section 2115 of the California Corporations Code is applicable
to us, certain laws of California relating to the indemnification of directors, officer and others also will govern.
At
present, there is no pending litigation or proceeding involving any of our directors or officers for which indemnification is
sought, nor are we aware of any threatened litigation that is likely to result in claims for indemnification. We also maintain
insurance policies that indemnify our directors and officers against various liabilities, including liabilities arising under
the Securities Act, which may be incurred by any director or officer in his or her capacity as such.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted for our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been informed that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event a claim for indemnification against such liabilities (other than payment by us for expenses incurred or paid by a
director, officer or controlling person of ours in successful defense of any action, suit, or proceeding) is asserted by a director,
officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction, the question of whether such
indemnification by it is against public policy in the Securities Act and will be governed by the final adjudication of such issue.
Anti-Takeover
Provisions of Nevada State Law
Some
features of the Nevada Revised Statutes, which are further described below, may have the effect of deterring third parties from
making takeover bids for control of us or may be used to hinder or delay a takeover bid. This would decrease the chance that our
stockholders would realize a premium over market price for their shares of common stock as a result of a takeover bid.
Acquisition
of Controlling Interest
The
Nevada Revised Statutes contain provisions governing acquisition of a controlling interest of a Nevada corporation. These provisions
provide generally that any person or entity that acquires a certain percentage of the outstanding voting shares of a Nevada corporation
may be denied voting rights with respect to the acquired shares, unless certain criteria are satisfied. Our Amended and Restated
Bylaws provide that these provisions will not apply to us or to any existing or future stockholder or stockholders.
Combination
with Interested Stockholder
The
Nevada Revised Statutes contain provisions governing the combination of a Nevada corporation that has 200 or more stockholders
of record with an interested stockholder. These provisions may have the effect of delaying or making it more difficult to affect
a change in control of our company.
A
corporation affected by these provisions may not engage in a combination within three years after the interested stockholder acquires
his, her or its shares unless the combination or purchase is approved by the board of directors before the interested stockholder
acquired such shares. Generally, if approval is not obtained, then after the expiration of the three-year period, the business
combination may be consummated with the approval of the board of directors before the person became an interested stockholder
or a majority of the voting power held by disinterested stockholders, or if the consideration to be received per share by disinterested
stockholders is at least equal to the highest of:
●
the highest price per share paid by the interested stockholder within the three years immediately preceding the date of the
announcement of the combination or within three years immediately before, or in, the transaction in which he, she or it
became an interested stockholder, whichever is higher;
●
the market value per share on the date of announcement of the combination or the date the person became an interested
stockholder, whichever is higher; or
●
if
higher for the holders of preferred stock, the highest liquidation value of the preferred stock, if any.
Generally,
these provisions define an interested stockholder as a person who is the beneficial owner, directly or indirectly of 10% or more
of the voting power of the outstanding voting shares of a corporation, and define combination to include any merger or consolidation
with an interested stockholder, or any sale, lease, exchange, mortgage, pledge, transfer or other disposition, in one transaction
or a series of transactions with an interested stockholder of assets of the corporation having:
●
an aggregate market value equal to 5% or more of the aggregate market value of the assets of the corporation;
●
an aggregate market value equal to 5% or more of the aggregate market value of all outstanding shares of the corporation;
or
●
representing 10% or more of the earning power or net income of the corporation.
Articles
of Incorporation and Bylaws
There
are no provisions in our articles of incorporation or our bylaws that would delay, defer or prevent a change in control of our
company and that would operate only with respect to an extraordinary corporate transaction involving our company or any of our
subsidiaries, such as merger, reorganization, tender offer, sale or transfer of substantially all of its assets, or liquidation.
Transfer
Agent
The
transfer agent for our common stock is Nevada Agency and Transfer Company. The transfer agent’s address is 50 West Liberty
Street, Suite 880, Reno, Nevada 89501.
DESCRIPTION
OF THE WARRANTS
General
We
may issue warrants for the purchase of our debt securities or common stock, or any combination thereof. Warrants may be issued
independently or together with our debt securities or common stock and may be attached to or separate from any offered securities.
The warrants may be issued under a warrant agreement that we enter into with a warrant agent, all as shall be set forth in a prospectus
supplement relating to the particular series of warrants being offered pursuant to this prospectus and such prospectus supplement.
This summary of certain provisions of the warrants is not complete. For the terms of a particular series of warrants, you should
refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series.
Debt
warrants
The
prospectus supplement relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt
warrants, including the following:
●
the
title of the debt warrants;
●
the offering price for the debt warrants, if any;
●
the aggregate number of the debt warrants;
●
the designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of the debt
warrants;
●
if applicable, the date from and after which the debt warrants and any debt securities issued with them will be separately
transferable;
●
the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the
warrants, which may be payable in cash, securities or other property;
●
the dates on which the right to exercise the debt warrants will commence and expire;
●
if applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time;
●
whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon exercise of
the debt warrants will be issued in registered or bearer form;
●
information with respect to book-entry procedures, if any; the currency or currency units in which the offering price, if
any, and the exercise price are payable;
●
if applicable, a discussion of material U.S. federal income tax considerations;
●
the antidilution provisions of the debt warrants, if any;
●
the redemption or call provisions, if any, applicable to the debt warrants;
●
any provisions with respect to the holder’s right to require us to repurchase the warrants upon a change in control or
similar event; and
●
any additional terms of the debt warrants, including procedures, and limitations relating to the exchange, exercise and
settlement of the debt warrants.
Debt
warrant certificates will be exchangeable for new debt warrant certificates of different denominations. Debt warrants may be exercised
at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise
of their debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable
upon exercise and will not be entitled to payment of principal or any premium, if any, or interest on the debt securities purchasable
upon exercise.
Equity
warrants
The
prospectus supplement relating to a particular series of warrants to purchase our common stock will describe the terms of the
warrants, including the following:
●
the title of the warrants;
●
the offering price for the warrants, if any;
●
the aggregate number of warrants;
●
the designation and terms of the common stock that may be purchased upon exercise of the warrants;
●
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants
issued with each security;
●
if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately
transferable;
●
the number of shares of common stock that may be purchased upon exercise of a warrant and the exercise price for the
warrants;
●
the dates on which the right to exercise the warrants shall commence and expire;
●
if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
●
the currency or currency units in which the offering price, if any, and the exercise price are payable;
●
if applicable, a discussion of material U.S. federal income tax considerations;
●
the
antidilution provisions of the warrants, if any;
●
the redemption or call provisions, if any, applicable to the warrants;
●
any provisions with respect to the holder’s right to require us to repurchase the warrants upon a change in control or
similar event; and
●
any additional terms of the warrants, including procedures, and limitations relating to the exchange, exercise and settlement
of the warrants.
Holders
of equity warrants will not be entitled:
●
to vote, consent or receive dividends;
●
receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other
matter; or
●
exercise any rights as stockholders of us.
DESCRIPTION
OF THE DEBT SECURITIES
The
debt securities may be either secured or unsecured and will either be our senior debt securities or our subordinated debt securities.
The debt securities will be issued under one or more separate indentures between us and a trustee to be specified in an accompanying
prospectus supplement. Senior debt securities will be issued under a senior indenture and subordinated debt securities will be
issued under a subordinated indenture. Together, the senior indenture and the subordinated indenture are called indentures in
this description. This prospectus, together with the applicable prospectus supplement, will describe the terms of a particular
series of debt securities.
The
following is a summary of selected provisions and definitions of the indentures and debt securities to which any prospectus supplement
may relate. The summary of selected provisions of the indentures and the debt securities appearing below is not complete and is
subject to, and qualified entirely by reference to, all of the provisions of the applicable indenture and certificates evidencing
the applicable debt securities. For additional information, you should look at the applicable indenture and the certificate evidencing
the applicable debt security that is filed as an exhibit to the registration statement that includes the prospectus. In this description
of the debt securities, the words “OncoSec,” “we,” “us,” or “our” refer only to
OncoSec Medical Incorporated and not to any of our subsidiaries, unless we expressly state or the context otherwise requires.
The
following description sets forth selected general terms and provisions of the applicable indenture and debt securities to which
any prospectus supplement may relate. Other specific terms of the applicable indenture and debt securities will be described in
the applicable prospectus supplement. If any particular terms of the indenture or debt securities described in a prospectus supplement
differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus
supplement.
General
Debt
securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate
principal amount for the debt securities of any series.
We
are not limited as to the amount of debt securities we may issue under the indentures. Unless otherwise provided in a prospectus
supplement, a series of debt securities may be reopened to issue additional debt securities of such series.
The
prospectus supplement relating to a particular series of debt securities will set forth:
●
whether the debt securities are senior or subordinated;
●
the offering price;
●
the title;
●
any limit on the aggregate principal amount;
●
the person who shall be entitled to receive interest, if other than the record holder on the record date;
●
the date or dates the principal will be payable;
●
the interest rate or rates, which may be fixed or variable, if any, the date from which interest will accrue, the interest
payment dates and the regular record dates, or the method for calculating the dates and rates;
●
the place where payments may be made;
●
any mandatory or optional redemption provisions or sinking fund provisions and any applicable redemption or purchase prices
associated with these provisions;
●
if issued other than in denominations of U.S. $1,000 or any multiple of U.S. $1,000, the denominations in which the debt
securities shall be issuable;
●
if applicable, the method for determining how the principal, premium, if any, or interest will be calculated by reference to
an index or formula;
●
if other than U.S. currency, the currency or currency units in which principal, premium, if any, or interest will be payable
and whether we or a holder may elect payment to be made in a different currency;
●
the portion of the principal amount that will be payable upon acceleration of maturity, if other than the entire principal
amount;
●
if the principal amount payable at stated maturity will not be determinable as of any date prior to stated maturity, the
amount or method for determining the amount which will be deemed to be the principal amount;
●
if applicable, whether the debt securities shall be subject to the defeasance provisions described below under
“Satisfaction and discharge; defeasance” or such other defeasance provisions specified in the applicable
prospectus supplement for the debt securities;
●
any conversion or exchange provisions;
●
whether the debt securities will be issuable in the form of a global security;
●
any subordination provisions applicable to the subordinated debt securities if different from those described below under
“Subordinated debt securities;”
●
any paying agents, authenticating agents, security registrars or other agents for the debt securities, if other than the
trustee;
●
any provisions relating to any security provided for the debt securities, including any provisions regarding the
circumstances under which collateral may be released or substituted;
●
any deletions of, or changes or additions to, the events of default, acceleration provisions or covenants;
●
any provisions relating to guaranties for the securities and any circumstances under which there may be additional obligors;
and
●
any other specific terms of such debt securities.
Unless
otherwise specified in the prospectus supplement, the debt securities will be registered debt securities. Debt securities may
be sold at a substantial discount below their stated principal amount, bearing no interest or interest at a rate which at time
of issuance is below market rates. The U.S. federal income tax considerations applicable to debt securities sold at a discount
will be described in the applicable prospectus supplement.
Exchange
and transfer
Debt
securities may be transferred or exchanged at the office of the security registrar or at the office of any transfer agent designated
by us.
We
will not impose a service charge for any transfer or exchange, but we may require holders to pay any tax or other governmental
charges associated with any transfer or exchange.
In
the event of any partial redemption of debt securities of any series, we will not be required to:
●
issue, register the transfer of, or exchange, any debt security of that series during a period beginning at the opening of
business 15 days before the day of mailing of a notice of redemption and ending at the close of business on the day of the
mailing; or
●
register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except
the unredeemed portion being redeemed in part.
We
will appoint the trustee as the initial security registrar. Any transfer agent, in addition to the security registrar initially
designated by us, will be named in the prospectus supplement. We may designate additional transfer agents or change transfer agents
or change the office of the transfer agent. However, we will be required to maintain a transfer agent in each place of payment
for the debt securities of each series.
Global
securities
The
debt securities of any series may be represented, in whole or in part, by one or more global securities. Each global security
will:
●
be registered in the name of a depositary, or its nominee, that we will identify in a prospectus supplement;
●
be deposited with the depositary or nominee or custodian; and
●
bear any required legends.
No
global security may be exchanged in whole or in part for debt securities registered in the name of any person other than the depositary
or any nominee unless:
●
the depositary has notified us that it is unwilling or unable to continue as depositary or has ceased to be qualified to act
as depositary;
●
an event of default is continuing with respect to the debt securities of the applicable series; or
●
any other circumstance described in a prospectus supplement has occurred permitting or requiring the issuance of any such
security.
As
long as the depositary, or its nominee, is the registered owner of a global security, the depositary or nominee will be considered
the sole owner and holder of the debt securities represented by the global security for all purposes under the indentures. Except
in the above limited circumstances, owners of beneficial interests in a global security will not be:
●
entitled to have the debt securities registered in their names;
●
entitled to physical delivery of certificated debt securities; or
●
considered to be holders of those debt securities under the indenture.
Payments
on a global security will be made to the depositary or its nominee as the holder of the global security. Some jurisdictions have
laws that require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws
may impair the ability to transfer beneficial interests in a global security.
Institutions
that have accounts with the depositary or its nominee are referred to as “participants.” Ownership of beneficial interests
in a global security will be limited to participants and to persons that may hold beneficial interests through participants. The
depositary will credit, on its book-entry registration and transfer system, the respective principal amounts of debt securities
represented by the global security to the accounts of its participants.
Ownership
of beneficial interests in a global security will be shown on and effected through records maintained by the depositary, with
respect to participants’ interests, or any participant, with respect to interests of persons held by participants on their
behalf.
Payments,
transfers and exchanges relating to beneficial interests in a global security will be subject to policies and procedures of the
depositary. The depositary policies and procedures may change from time to time. Neither any trustee nor we will have any responsibility
or liability for the depositary’s or any participant’s records with respect to beneficial interests in a global security.
Payment
and paying agents
Unless
otherwise indicated in a prospectus supplement, the provisions described in this paragraph will apply to the debt securities.
Payment of interest on a debt security on any interest payment date will be made to the person in whose name the debt security
is registered at the close of business on the regular record date. Payment on debt securities of a particular series will be payable
at the office of a paying agent or paying agents designated by us. However, at our option, we may pay interest by mailing a check
to the record holder. The trustee will be designated as our initial paying agent.
We
may also name any other paying agents in a prospectus supplement. We may designate additional paying agents, change paying agents
or change the office of any paying agent. However, we will be required to maintain a paying agent in each place of payment for
the debt securities of a particular series.
All
moneys paid by us to a paying agent for payment on any debt security that remain unclaimed for a period ending the earlier of:
●
10 business days prior to the date the money would be turned over to the applicable state; or
●
at the end of two years after such payment was due,
will
be repaid to us thereafter. The holder may look only to us for such payment.
No
protection in the event of a change of control
Unless
otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will
not contain any provisions that may afford holders of the debt securities protection in the event we have a change in control
or in the event of a highly leveraged transaction, whether or not such transaction results in a change in control.
Covenants
Unless
otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will
not contain any financial or restrictive covenants.
Consolidation,
merger and sale of assets
Unless
we indicate otherwise in a prospectus supplement with respect to a particular series of debt securities, we may not consolidate
with or merge into any other person (other than a subsidiary of us), in a transaction in which we are not the surviving corporation,
or convey, transfer or lease our properties and assets substantially as an entirety to, any person (other than a subsidiary of
us), unless:
●
the successor entity, if any, is a U.S. corporation, limited liability company, partnership, trust or other business
entity;
●
the successor entity assumes our obligations on the debt securities and under the indentures;
●
immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing;
and
●
certain other conditions specified in the indenture are met.
Events
of default
Unless
we indicate otherwise in a prospectus supplement, the following will be events of default for any series of debt securities under
the indentures:
(1)
we fail to pay principal of or any premium on any debt security of that series when due;
(2)
we fail to pay any interest on any debt security of that series for 60 days after it becomes due;
(3)
we fail to deposit any sinking fund payment when due;
(4)
we fail to perform any other covenant in the indenture and such failure continues for 90 days after we are given the notice required
in the indentures; and
(5)
certain events involving our bankruptcy, insolvency or reorganization.
Additional
or different events of default applicable to a series of debt securities may be described in a prospectus supplement. An event
of default of one series of debt securities is not necessarily an event of default for any other series of debt securities.
The
trustee may withhold notice to the holders of any default, except defaults in the payment of principal, premium, if any, interest,
any sinking fund installment on, or with respect to any conversion right of, the debt securities of such series. However, the
trustee must consider it to be in the interest of the holders of the debt securities of such series to withhold this notice.
Unless
we indicate otherwise in a prospectus supplement, if an event of default, other than an event of default described in clause (5)
above, shall occur and be continuing with respect to any series of debt securities, either the trustee or the holders of at least
a 25 percent in aggregate principal amount of the outstanding securities of that series may declare the principal amount and premium,
if any, of the debt securities of that series, or if any debt securities of that series are original issue discount securities,
such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest,
if any, thereon, to be due and payable immediately.
Unless
we indicate otherwise in a prospectus supplement, if an event of default described in clause (5) above shall occur, the principal
amount and premium, if any, of all the debt securities of that series, or if any debt securities of that series are original issue
discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with
accrued and unpaid interest, if any, thereon, will automatically become immediately due and payable. Any payment by us on the
subordinated debt securities following any such acceleration will be subject to the subordination provisions described below under
“Subordinated debt securities.”
Notwithstanding
the foregoing, each indenture will provide that we may, at our option, elect that the sole remedy for an event of default relating
to our failure to comply with our obligations described under the section entitled “Reports” below or our failure
to comply with the requirements of Section 314(a)(1) of the Trust Indenture Act will for the first 180 days after the occurrence
of such an event of default consist exclusively of the right to receive additional interest on the relevant series of debt securities
at an annual rate equal to (i) 0.25% of the principal amount of such series of debt securities for the first 90 days after the
occurrence of such event of default and (ii) 0.50% of the principal amount of such series of debt securities from the 91st day
to, and including, the 180th day after the occurrence of such event of default, which we call “additional interest.”
If we so elect, the additional interest will accrue on all outstanding debt securities from and including the date on which such
event of default first occurs until such violation is cured or waived and shall be payable on each relevant interest payment date
to holders of record on the regular record date immediately preceding the interest payment date. On the 181st day after such event
of default (if such violation is not cured or waived prior to such 181st day), the debt securities will be subject to acceleration
as provided above. In the event we do not elect to pay additional interest upon any such event of default in accordance with this
paragraph, the debt securities will be subject to acceleration as provided above.
In
order to elect to pay the additional interest as the sole remedy during the first 180 days after the occurrence of any event of
default relating to the failure to comply with the reporting obligations in accordance with the preceding paragraph, we must notify
all holders of debt securities and the trustee and paying agent of such election prior to the close of business on the first business
day following the date on which such event of default occurs. Upon our failure to timely give such notice or pay the additional
interest, the debt securities will be immediately subject to acceleration as provided above.
After
acceleration, the holders of a majority in aggregate principal amount of the outstanding securities of that series may, under
certain circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated
principal, or other specified amounts or interest, have been cured or waived.
Other
than the duty to act with the required care during an event of default, the trustee will not be obligated to exercise any of its
rights or powers at the request of the holders unless the holders shall have offered to the trustee reasonable indemnity. Generally,
the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the right to
direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust
or power conferred on the trustee.
A
holder of debt securities of any series will not have any right to institute any proceeding under the indentures, or for the appointment
of a receiver or a trustee, or for any other remedy under the indentures, unless:
(1)
the holder has previously given to the trustee written notice of a continuing event of default with respect to the debt securities
of that series;
(2)
the holders of at least 25 percent in aggregate principal amount of the outstanding debt securities of that series have made a
written request and have offered reasonable indemnity to the trustee to institute the proceeding; and
(3)
the trustee has failed to institute the proceeding and has not received direction inconsistent with the original request from
the holders of a majority in aggregate principal amount of the outstanding debt securities of that series within 60 days after
the original request.
Holders
may, however, sue to enforce the payment of principal, premium or interest on any debt security on or after the due date or to
enforce the right, if any, to convert any debt security (if the debt security is convertible) without following the procedures
listed in (1) through (3) above.
We
will furnish the trustee an annual statement from our officers as to whether or not we are in default in the performance of the
conditions and covenants under the indenture and, if so, specifying all known defaults.
Modification
and waiver
Unless
we indicate otherwise in a prospectus supplement, the applicable trustee and we may make modifications and amendments to an indenture
with the consent of the holders of a majority in aggregate principal amount of the outstanding securities of each series affected
by the modification or amendment.
We
may also make modifications and amendments to the indentures for the benefit of holders without their consent, for certain purposes
including, but not limited to:
●
providing for our successor to assume the covenants under the indenture;
●
adding covenants or events of default;
●
making certain changes to facilitate the issuance of the securities;
●
securing the securities;
●
providing for a successor trustee or additional trustees;
●
curing any ambiguities or inconsistencies;
●
providing for guaranties of, or additional obligors on, the securities;
●
permitting or facilitating the defeasance and discharge of the securities; and
●other
changes specified in the indenture.
However,
neither the trustee nor we may make any modification or amendment without the consent of the holder of each outstanding security
of that series affected by the modification or amendment if such modification or amendment would:
●
change the stated maturity of any debt security;
●
reduce the principal, premium, if any, or interest on any debt security or any amount payable upon redemption or repurchase,
whether at our option or the option of any holder, or reduce the amount of any sinking fund payments;
●
reduce the principal of an original issue discount security or any other debt security payable on acceleration of
maturity;
●
change the place of payment or the currency in which any debt security is payable;
●
impair the right to enforce any payment after the stated maturity or redemption date;
●
if subordinated debt securities, modify the subordination provisions in a materially adverse manner to the
holders;
●
adversely affect the right to convert any debt security if the debt security is a convertible debt security; or
●
change the provisions in the indenture that relate to modifying or amending the indenture.
Satisfaction
and discharge; defeasance
We
may be discharged from our obligations on the debt securities, subject to limited exceptions, of any series that have matured
or will mature or be redeemed within one year if we deposit enough money with the trustee to pay all the principal, interest and
any premium due to the stated maturity date or redemption date of the debt securities.
Each
indenture contains a provision that permits us to elect either or both of the following:
●
we may elect to be discharged from all of our obligations, subject to limited exceptions, with respect to any series of debt
securities then outstanding. If we make this election, the holders of the debt securities of the series will not be entitled
to the benefits of the indenture, except for the rights of holders to receive payments on debt securities or the registration
of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities.
●
we may elect to be released from our obligations under some or all of any financial or restrictive covenants applicable to
the series of debt securities to which the election relates and from the consequences of an event of default resulting from a
breach of those covenants.
To
make either of the above elections, we must irrevocably deposit in trust with the trustee enough money to pay in full the principal,
interest and premium on the debt securities. This amount may be made in cash and/or U.S. government obligations or, in the case
of debt securities denominated in a currency other than U.S. dollars, cash in the currency in which such series of securities
is denominated and/or foreign government obligations. As a condition to either of the above elections, for debt securities denominated
in U.S. dollars we must deliver to the trustee an opinion of counsel that the holders of the debt securities will not recognize
income, gain or loss for U.S. federal income tax purposes as a result of the action.
With
respect to debt securities of any series that are denominated in a currency other than United States dollars, “foreign government
obligations” means:
●
direct obligations of the government that issued or caused to be issued the currency in which such securities are denominated
and for the payment of which obligations its full faith and credit is pledged, or, with respect to debt securities of any
series which are denominated in Euros, direct obligations of certain members of the European Union for the payment of which
obligations the full faith and credit of such members is pledged, which in each case are not callable or redeemable at the
option of the issuer thereof; or
●
obligations of a person controlled or supervised by or acting as an agency or instrumentality of a government described in
the bullet above the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by such
government, which are not callable or redeemable at the option of the issuer thereof.
Reports
The
indentures provide that any reports or documents that we file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act
will be filed with the trustee within 15 days after the same is filed with the SEC. Documents filed by us with the SEC via the
EDGAR system will be deemed filed with the trustee as of the time such documents are filed with the SEC.
Notices
Notices
to holders will be given by mail to the addresses of the holders in the security register.
Governing
law
The
indentures and the debt securities will be governed by, and construed under, the laws of the State of New York.
No
personal liability of directors, officers, employees and stockholders
No
incorporator, stockholder, employee, agent, officer, director or subsidiary of ours will have any liability for any obligations
of ours, or because of the creation of any indebtedness under the debt securities, the indentures or supplemental indentures.
The indentures provide that all such liability is expressly waived and released as a condition of, and as a consideration for,
the execution of such indentures and the issuance of the debt securities.
Regarding
the trustee
The
indentures limit the right of the trustee, should it become our creditor, to obtain payment of claims or secure its claims.
The
trustee will be permitted to engage in certain other transactions with us. However, if the trustee acquires any conflicting interest,
and there is a default under the debt securities of any series for which it is trustee, the trustee must eliminate the conflict
or resign.
Subordinated
debt securities
The
following provisions will be applicable with respect to each series of subordinated debt securities, unless otherwise stated in
the prospectus supplement relating to that series of subordinated debt securities.
The
indebtedness evidenced by the subordinated debt securities of any series is subordinated, to the extent provided in the subordinated
indenture and the applicable prospectus supplement, to the prior payment in full, in cash or other payment satisfactory to the
holders of senior debt, of all senior debt, including any senior debt securities.
Upon
any distribution of our assets upon any dissolution, winding up, liquidation or reorganization, whether voluntary or involuntary,
marshalling of assets, assignment for the benefit of creditors, or in bankruptcy, insolvency, receivership or other similar proceedings,
payments on the subordinated debt securities will be subordinated in right of payment to the prior payment in full in cash or
other payment satisfactory to holders of senior debt of all senior debt.
In
the event of any acceleration of the subordinated debt securities of any series because of an event of default with respect to
the subordinated debt securities of that series, holders of any senior debt would be entitled to payment in full in cash or other
payment satisfactory to holders of senior debt of all senior debt before the holders of subordinated debt securities are entitled
to receive any payment or distribution.
In
addition, the subordinated debt securities will be structurally subordinated to all indebtedness and other liabilities of our
subsidiaries, including trade payables and lease obligations. This occurs because our right to receive any assets of our subsidiaries
upon their liquidation or reorganization, and your right to participate in those assets, will be effectively subordinated to the
claims of that subsidiary’s creditors, including trade creditors, except to the extent that we are recognized as a creditor
of such subsidiary. If we are recognized as a creditor of that subsidiary, our claims would still be subordinate to any security
interest in the assets of the subsidiary and any indebtedness of the subsidiary senior to us.
We
are required to promptly notify holders of senior debt or their representatives under the subordinated indenture if payment of
the subordinated debt securities is accelerated because of an event of default.
Under
the subordinated indenture, we may also not make payment on the subordinated debt securities if:
●
a default in our obligations to pay principal, premium, if any, interest or other amounts on our senior debt occurs and the
default continues beyond any applicable grace period, which we refer to as a payment default; or
●
any other default occurs and is continuing with respect to designated senior debt that permits holders of designated senior
debt to accelerate its maturity, which we refer to as a non-payment default, and the trustee receives a payment blockage
notice from us or some other person permitted to give the notice under the subordinated indenture.
We
will resume payments on the subordinated debt securities:
●
in case of a payment default, when the default is cured or waived or ceases to exist, and
●
in case of a nonpayment default, the earlier of when the default is cured or waived or ceases to exist or 179 days after the
receipt of the payment blockage notice.
No
new payment blockage period may commence on the basis of a nonpayment default unless 365 days have elapsed from the effectiveness
of the immediately prior payment blockage notice. No nonpayment default that existed or was continuing on the date of delivery
of any payment blockage notice to the trustee shall be the basis for a subsequent payment blockage notice.
As
a result of these subordination provisions, in the event of our bankruptcy, dissolution or reorganization, holders of senior debt
may receive more, ratably, and holders of the subordinated debt securities may receive less, ratably, than our other creditors.
The subordination provisions will not prevent the occurrence of any event of default under the subordinated indenture.
The
subordination provisions will not apply to payments from money or government obligations held in trust by the trustee for the
payment of principal, interest and premium, if any, on subordinated debt securities pursuant to the provisions described under
the section entitled “Satisfaction and discharge; defeasance,” if the subordination provisions were not violated at
the time the money or government obligations were deposited into trust.
If
the trustee or any holder receives any payment that should not have been made to them in contravention of subordination provisions
before all senior debt is paid in full in cash or other payment satisfactory to holders of senior debt, then such payment will
be held in trust for the holders of senior debt.
Senior
debt securities will constitute senior debt under the subordinated indenture.
Additional
or different subordination provisions may be described in a prospectus supplement relating to a particular series of debt securities.
Definitions
“Designated
senior debt” means our obligations under any particular senior debt in which the instrument creating or evidencing the same
or the assumption or guarantee thereof, or related agreements or documents to which we are a party, expressly provides that such
indebtedness shall be designated senior debt for purposes of the subordinated indenture. The instrument, agreement or other document
evidencing any designated senior debt may place limitations and conditions on the right of such senior debt to exercise the rights
of designated senior debt.
“Indebtedness”
means the following, whether absolute or contingent, secured or unsecured, due or to become due, outstanding on the date of the
indenture for such series of securities or thereafter created, incurred or assumed:
●
our indebtedness evidenced by a credit or loan agreement, note, bond, debenture or other written obligation;
●
all of our obligations for money borrowed;
●
all of our obligations evidenced by a note or similar instrument given in connection with the acquisition of any businesses,
properties or assets of any kind;
●
our obligations:
●
as lessee under leases required to be capitalized on the balance sheet of the lessee under generally accepted accounting
principles, or
●
as lessee under leases for facilities, capital equipment or related assets, whether or not capitalized, entered into or
leased for financing purposes;
●
all of our obligations under interest rate and currency swaps, caps, floors, collars, hedge agreements, forward contracts or
similar agreements or arrangements;
●
all of our obligations with respect to letters of credit, bankers’ acceptances and similar facilities, including
reimbursement obligations with respect to the foregoing;
●
all of our obligations issued or assumed as the deferred purchase price of property or services, but excluding trade accounts
payable and accrued liabilities arising in the ordinary course of business;
●
all obligations of the type referred to in the above clauses of another person, the payment of which, in either case, we have
assumed or guaranteed, for which we are responsible or liable, directly or indirectly, jointly or severally, as obligor,
guarantor or otherwise, or which are secured by a lien on our property; and
●
renewals, extensions, modifications, replacements, restatements and refundings of, or any indebtedness or obligation issued
in exchange for, any such indebtedness or obligation described in the above clauses of this definition.
“Senior
debt” means the principal of, premium, if any, and interest, including all interest accruing subsequent to the commencement
of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such
proceeding, and rent payable on or in connection with, and all fees and other amounts payable in connection with, our indebtedness.
However, senior debt shall not include:
●
any debt or obligation if its terms or the terms of the instrument under which or pursuant to which it is issued expressly
provide that it shall not be senior in right of payment to the subordinated debt securities or expressly provide that such
indebtedness is on the same basis or “junior” to the subordinated debt securities; or
●
debt to any of our subsidiaries, a majority of the voting stock of which is owned, directly or indirectly, by us.
“Subsidiary”
means a corporation more than 50% of the outstanding voting stock of which is owned, directly or indirectly, by us or by one or
more or our other subsidiaries or by a combination of us and our other subsidiaries. For purposes of this definition, “voting
stock” means stock or other similar interests which ordinarily has or have voting power for the election of directors, or
persons performing similar functions, whether at all times or only so long as no senior class of stock or other interests has
or have such voting power by reason of any contingency.
PLAN
OF DISTRIBUTION
We
may sell the securities offered through this prospectus (1) to or through underwriters or dealers, (2) directly to purchasers,
including our affiliates, (3) through agents, or (4) through a combination of any these methods. The securities may be distributed
at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing
market prices, or negotiated prices. The prospectus supplement will include the following information:
●
the terms of the offering;
●
the names of any underwriters or agents;
●
the name or names of any managing underwriter or underwriters;
●
the purchase price of the securities;
●
the net proceeds from the sale of the securities;
●
any delayed delivery arrangements;
●
any underwriting discounts, commissions and other items constituting underwriters’ compensation;
●
any initial public offering price;
●
any discounts or concessions allowed or reallowed or paid to dealers; and
●
any commissions paid to agents.
Sale
through underwriters or dealers
If
underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting,
purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one
or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions
in any of our other securities (described in this prospectus or otherwise), including other public or private transactions and
short sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more
managing underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement,
the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will
be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time
any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers.
If
dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals.
They may then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus
supplement will include the names of the dealers and the terms of the transaction.
Direct
sales and sales through agents
We
may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such
securities may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved
in the offer or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise indicated
in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its
appointment.
We
may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning
of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus
supplement.
Underwriter,
dealer or agent discounts and commissions
Underwriters,
dealers or agents may receive compensation in the form of discounts, concessions or commissions from us or our purchasers as their
agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under
the Securities Act. As a result, discounts, commissions, or profits on resale received by the underwriters, dealers or agents
may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any such underwriter, dealer
or agent, and describe any compensation received by them from us. Any initial public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time. The maximum commission or discount to be received by
any underwriter, dealer or agent will not be greater than eight percent (8%) of the maximum gross proceeds of the securities that
may be sold under this prospectus.
Delayed
delivery contracts
If
the prospectus supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of
institutions to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide
for payment and delivery on a specified date in the future. The contracts would be subject only to those conditions described
in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those
contracts.
Market
making, stabilization and other transactions
Unless
the applicable prospectus supplement states otherwise, each series of offered securities will be a new issue and will have no
established trading market. We may elect to list any series of offered securities on an exchange. Any underwriters that we use
in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time without
notice. Therefore, we cannot assure you that the securities will have a liquid trading market.
Any
underwriter may also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule
104 under the Securities Exchange Act. Stabilizing transactions involve bids to purchase the underlying security in the open market
for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases
of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.
Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the
syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions,
syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence
of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time.
Derivative
transactions and hedging
We,
the underwriters or other agents may engage in derivative transactions involving the securities. These derivatives may consist
of short sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the
securities, hold or resell securities acquired and purchase options or futures on the securities and other derivative instruments
with returns linked to or related to changes in the price of the securities. In order to facilitate these derivative transactions,
we may enter into security lending or repurchase agreements with the underwriters or agents. The underwriters or agents may effect
the derivative transactions through sales of the securities to the public, including short sales, or by lending the securities
in order to facilitate short sale transactions by others. The underwriters or agents may also use the securities purchased or
borrowed from us or others (or, in the case of derivatives, securities received from us in settlement of those derivatives) to
directly or indirectly settle sales of the securities or close out any related open borrowings of the securities.
Electronic
auctions
We
may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities
directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms
of electronic bidding or ordering systems for the pricing and allocation of such securities, you should pay particular attention
to the description of that system we will provide in a prospectus supplement.
Such
electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional
offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which
such securities are sold. These bidding or ordering systems may present to each bidder, on a so-called “real-time”
basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based
on the bids submitted, and whether a bidder’s individual bids would be accepted, prorated or rejected. For example, in the
case of a debt security, the clearing spread could be indicated as a number of “basis points” above an index treasury
note. Of course, many pricing methods can and may also be used.
Upon
completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors.
The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole
or in part on the results of the Internet or other electronic bidding process or auction.
General
information
Agents,
underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities,
including liabilities under the Securities Act.
LEGAL
MATTERS
Unless
otherwise indicated in the applicable prospectus supplement, the validity of the securities being offered pursuant to this prospectus
will be passed upon by McDonald Carano Wilson LLP, Reno, Nevada, and Morrison & Foerster LLP, San Diego, California. Any underwriters
will be advised about legal matters relating to any offering by their own legal counsel.
EXPERTS
The
consolidated financial statements of OncoSec Medical Incorporated, a development stage company, appearing in the Company’s
Annual Report on Form 10-K for the fiscal year ended July 31, 2013, filed with the SEC on September 27, 2013, have been audited
by Mayer Hoffman McCann P.C., an independent registered public accounting firm, as stated in its report therein, and are incorporated
by reference. Such audited consolidated financial statements are incorporated hereby by reference in reliance upon such report
of such firm given upon its authority as experts in accounting and auditing.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The
SEC allows us to “incorporate by reference” the information we file with it. This means that we can disclose important
information to you in this prospectus by referring you to another document. The information incorporated by reference is considered
to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information
contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below
that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed “filed” pursuant
to the General Instructions of Form 8-K):
●
our Annual Report on Form 10-K for the fiscal year ended July 31, 2013 filed with the SEC on September 27, 2013;
●
our Quarterly Reports on Form 10-Q for the quarters ended October 31, 2013 and January 31, 2014 and filed with the SEC on
December 16, 2013 and March 14, 2014, respectively;
●
our Current Reports on Form 8-K filed with the SEC on September 19, 2013, December 17, 2013 and March 13, 2014;
and
●
the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on March 31, 2011,
including any amendments or reports filed for the purpose of updating such description.
We
also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file
with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement,
but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document
incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent
that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies
or supersedes that statement.
We
will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, on written or oral
request of that person, a copy of any or all of the documents we are incorporating by reference into this prospectus, other than
exhibits to those documents unless such exhibits are specifically incorporated by reference into those documents. Such written
requests should be addressed to:
OncoSec
Medical Incorporated
9810
Summers Ridge Drive, Suite 110
San
Diego, California 92121
Attention:
Investor Relations
You
may also make such requests by contacting us at (858) 662-6732.
WHERE
YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and current reports and proxy statements and other information with the SEC. You may read and copy any
document that we file at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the
SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC filings are also available on the SEC’s
web site at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our web site at http://www.oncosec.com.
We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be
a part of this document.
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024